Peps
What is TP-508?
TP-508, also called rusalatide acetate or Chrysalin, is a lab-made 23-amino-acid peptide copied from part of thrombin, a protein involved in blood clotting and tissue repair. It was tested in people for diabetic foot ulcers and wrist fractures. A large phase 3 fracture trial missed its main goal, no later human trials are registered, and it is not approved.
Biological role or research focus
Wound, fracture and radiation-injury research.
A small pilot trial whose reported benefits come from the per-protocol group, not necessarily everyone randomized, and the heel-ulcer result rests on 12 ulcers. No larger diabetic foot ulcer trial was found, and the later phase 3 fracture trial missed its main clinical goal.
Role reference: Thrombin peptide Chrysalin stimulates healing of diabetic foot ulcers in a placebo-controlled phase I/II study · 2007 ↗
Names you may encounter
TP508 · Rusalatide acetate · Rusalatide · Chrysalin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Synthetic 23-amino-acid peptide copied from part of thrombin, a blood-clotting protein
- Research focus
- Wound, fracture and radiation-injury research
- Featured evidence
- Human randomized phase 1/2 trial
- Source check
- October 15, 2026
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| TP-508 (Chrysalin) applied to diabetic foot ulcers (2007) | Human randomized phase 1/2 trial | 60 adults with diabetic foot ulcers receiving standardized wound care and off-loading. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized phase 1/2 trial · 2007
TP-508 (Chrysalin) applied to diabetic foot ulcers
What did this publication test, and what did it find?
- Population / model
- 60 adults with diabetic foot ulcers receiving standardized wound care and off-loading.
- Study design
- Prospective, randomized, double-blind, placebo-controlled phase 1/2 trial. TP-508 dissolved in saline, or saline alone, was applied to the ulcer alongside standard care, and two strengths of TP-508 were compared with placebo.
- Main finding
- Among participants treated as planned (per protocol), complete healing was more than twice as common with TP-508 as with placebo, the average closure rate was about 80% higher, and median time to full closure was about 40% shorter. Heel ulcers showed the largest difference: 6 of 7 healed completely with TP-508 versus 0 of 5 with placebo. Wound reactions and adverse events were similar between groups.
- Limits & context
- A small pilot trial whose reported benefits come from the per-protocol group, not necessarily everyone randomized, and the heel-ulcer result rests on 12 ulcers. No larger diabetic foot ulcer trial was found, and the later phase 3 fracture trial missed its main clinical goal.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming TP-508 as an intervention was found on ClinicalTrials.gov when we last checked (October 15, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Search additional PubMed records ↗Risks & interactions
TP-508 is an unapproved thrombin-derived peptide. In a small foot-ulcer trial, side effects were similar to placebo, but human safety data are limited and long-term effects are unknown.
A 60-person diabetic foot ulcer trial reported similar adverse events with TP-508 and placebo and no drug-related serious adverse events. Fracture trials were larger, but their detailed safety results were not available in the abstracts checked.
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: TP-508 (Chrysalin) in diabetic foot ulcers, phase 1/2 (Wound Repair Regen, 2007) ↗ · Rusalatide acetate review including the phase 3 fracture trial (Expert Opin Pharmacother, 2008) ↗
Safety & what remains unknown
In the foot-ulcer pilot, local wound reactions and adverse events were similar with TP-508 and placebo, with no reported drug-related laboratory changes or serious adverse events. Detailed safety results from the fracture trials were not available in the abstracts checked, and effects of repeated or long-term use are unknown.
Evidence boundaries
A small pilot trial whose reported benefits come from the per-protocol group, not necessarily everyone randomized, and the heel-ulcer result rests on 12 ulcers. No larger diabetic foot ulcer trial was found, and the later phase 3 fracture trial missed its main clinical goal.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA, checked October 15, 2026). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (checked October 15, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. As an unapproved substance it is likely covered by S0 (prohibited at all times) unless another section applies; its reported effects on blood-vessel growth and tissue repair could also bring it under S2.3 growth factor modulators. source
Other notes
- A fracture study of Chrysalin (NCT00131482) was terminated in 2007 because treatment did not demonstrate benefit compared with placebo; no later TP-508 trials are registered (checked October 15, 2026). source
Checked October 8, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile covers an investigational drug whose clinical development stalled. In a large phase 3 trial in distal radius (wrist) fractures, TP-508 sped healing seen on X-rays but did not meet its main clinical goal, the time until the wrist no longer needed immobilization, across all participants; its developers reported a benefit in a subgroup of women with low bone density. A separate fracture study on ClinicalTrials.gov was terminated in 2007 because treatment did not show benefit over placebo, and no later human trials are registered (checked October 15, 2026). It is not approved anywhere, and sellers list it as a research chemical.
Later research by the laboratory that studies TP-508 tested it against radiation injury: it helped irradiated human blood-vessel cells recover and repair DNA damage in the lab, and improved survival in mice given high-dose radiation. These are laboratory and animal results; no human radiation trials were found.
Source: Nuclear countermeasure activity of TP508 in mice · 2016 ↗
Source: ClinicalTrials.gov · NCT00131482 · Chrysalin in adults with a broken wrist ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
Some seller links are affiliate links, and codes such as PEPSRADAR credit PepsRadar; PepsRadar may earn a commission. Affiliate disclosure. For laboratory research use only. Not for human consumption.
TP-508 (rusalatide) (10 mg)
Disguised Alpha · Vendor-labeled research use only
$119.99 · from $12.00/mg
Listed out of stock · Snapshot 2026-10-15
Options may vary. Shipping and tax excluded.
10% off with code PEPSRADAR · PepsRadar earns a commission on this code
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides, Alera Research, Pinnacle Peptide Labs, Certified Pep, Peptide.Express, Purgo Labs, Offline Peptides, Ascension Peptides, OMNI Peptides, Disguised Alpha. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Biology & proposed mechanism
Thrombin and fragments of it help start tissue repair after an injury. TP-508 represents one region of thrombin that, in laboratory and animal studies, stimulated cells involved in wound healing and the growth of new blood vessels. Those proposed effects come from preclinical work and were not confirmed by a successful late-stage human trial.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Questions worth asking
- Did TP-508 work in its large fracture trial?
- What material, population, and route were actually studied?
- A small pilot trial whose reported benefits come from the per-protocol group, not necessarily everyone randomized, and the heel-ulcer result rests on 12 ulcers. No larger diabetic foot ulcer trial was found, and the later phase 3 fracture trial missed its main clinical goal.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 29 caption files are indexed from 18,167 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Frequently asked questions
Did TP-508 work in its large fracture trial?
Not on its main goal. It sped healing seen on X-rays, but it did not shorten the time until the wrist could come out of immobilization across all participants. A benefit was reported only in a subgroup of women with low bone density, which would need a new trial to confirm.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
- PubMed · PMID 17244316 ↗
- Could rusalatide acetate be the future drug of choice for diabetic foot ulcers and fracture repair? (review) · 2008 ↗
- Nuclear countermeasure activity of TP508 in mice · 2016 ↗
- ClinicalTrials.gov · NCT00131482 · Chrysalin in adults with a broken wrist ↗
Source notes checked 2026-10-15. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.